MSD has only just completed its $10 billion takeover of Verona Pharma, but is still on the hunt for more bolt-on acquisitions to flesh out its pipeline, according to chief executive Rob Davis. On the ...
MSD has fleshed out the results of phase 3 trials of its cholesterol-lowering, oral PCSK9 inhibitor, enlicitide decanoate, showing its efficacy was comparable to that of injectable alternatives. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback